Adlai Nortye (ANL) Common Equity (2022 - 2025)
Adlai Nortye (ANL) reported Common Equity of -$8.3 million for Q4 2025, down 132.65% year-over-year from $25.5 million in Q4 2024, and down 205.06% on a QoQ basis from $7.9 million in Q2 2025.
Adlai Nortye (ANL) has 4 years of Common Equity data on file, last reported at -$8.3 million in Q4 2025.
- Quarterly Common Equity fell 132.65% year-over-year to -$8.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$8.3 million (down 132.65% YoY) and the FY2025 annual result came in at -$8.3 million, down 132.65% from the prior year.
- Common Equity slipped to -$8.3 million in Q4 2025 per ANL's latest filing, from $7.9 million in the prior quarter.
- Across five years, Common Equity topped out at $75.0 million in Q4 2023 and bottomed at -$241.3 million in Q4 2022.
- The 4-year median for Common Equity is $16.7 million (2024), against an average of -$14.6 million.
- The widest annual swing landed in 2023, when Common Equity jumped 131.1%; it then slumped 132.65% in 2025.
- Tracing ANL's Common Equity over 4 years: stood at -$241.3 million in 2022, then surged by 131.1% to $75.0 million in 2023, then sank by 66.04% to $25.5 million in 2024, then tumbled by 132.65% to -$8.3 million in 2025.
- Per Business Quant, the three latest ANL Common Equity figures stand at -$8.3 million (Q4 2025), $7.9 million (Q2 2025), and $25.5 million (Q4 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | -1.42 Mn |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | 35.63 Mn |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | 14.38 Mn |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 19.36 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 31.42 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | 13.21 Mn |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 1.08 Bn |
| 10 | Adlai Nortye | 23,840.00 | -8.03 Mn | - | -8.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -8.32 Mn |
| Jun 30, 2025 | 7.92 Mn |
| Dec 31, 2024 | 25.49 Mn |
| Jun 30, 2024 | 53.37 Mn |
| Dec 31, 2023 | 75.05 Mn |
| Dec 31, 2022 | -241.29 Mn |